Medicaid fee-for-service (FFS) programs are more likely to cover treatments for opioid use disorder (OUD) than Medicaid managed care plans. Medicaid covers around 40% of Americans with OUD, but OUD treatment access varies across Medicaid FFS programs. All 39 Medicaid FFS programs covered buprenorphine, 32 covered methadone (82.1%), and 37 covered injectable naltrexone (94.9%). In comparison, 255 MCO plans covered buprenorphine (98.1%), 164 covered methadone (69.5%), and 188 covered injectable naltrexone (71.2%).

Almost all beneficiaries in both FFS programs and MCO plans had buprenorphine coverage. However, MCO beneficiaries were less likely than FFS . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.